Highlights
NASDAQ: INCY       Incyte Corporation
Last Price Today's Change   Day's Range   Trading Volume
123.77   -0.62 (0.50%)  123.15 - 125.47  487,404

Overview

Avg Volume (4 weeks):0
4 Weeks Range:122.51 - 144.32
52 Weeks Range:68.03 - 153.15
Average Price Target: 120.00
Price Target Upside/Downside: -3.77

Headlines



No recent Headlines for this stock.


Business Background

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.

  Be the first to like this.
 


 

4720  2281  573  751 

ActiveGainersLosers
Top 10 Active Counters
 NameLastChange 
 CSQ 11.43+0.02 
 BNCL 16.95+0.35 
 GALT 3.129-0.141 
 BBRY 9.190.00 
 NUGT 7.765-0.405 
 X 23.297-7.813 
 TWTR 15.981+1.321 
 BAC 24.13+0.15 
 SPY 239.34+0.79 
 EEM 40.08-0.12 
Partners & Brokers